Xiberlinc

Xiberlinc operates at the intersection of applied neuroscience, neurotechnology, consulting, and wellness. Its described work combines cognitive assessments and digital brain-health services with support for innovation and product development, giving it a service-led profile rather than a clearly documented standalone software or device business. The company’s stated differentiators include EEG-based evaluation of anticipatory excitement, a three-axis framework for analyzing emotional responses and cognition, and a Brain Emotion Interface (BEI) approach described as estimating brain activity states from audiovisual information. Its materials also emphasize combining neuroscience, psychology, engineering, design, and business expertise, alongside research ethics and privacy considerations. The available company information does not identify named competitors, customers, or market-share figures, so a direct competitive ranking is not supportable. Relevant comparison groups would include providers of EEG-based assessment, affective-computing tools, and neuroscience-led R&D consulting, but no specific competitor names can be established from the available profile. Xiberlinc’s market position is therefore best understood as a specialized research-and-services offering with a stated emphasis on connecting brain science to business and product applications.

Xiberlinc’s trajectory is anchored by its Apr 1, 2022 founding and Maro Machizawa’s CEO role, which began in April 2022. Its listed portfolio encompasses consulting, cognitive assessments, digital brain-health services, and Brain Emotion Interface technology, suggesting a model that spans expert services and applied technology rather than a single documented product line. The company describes EEG-based analysis and real-time evaluation of emotional and cognitive responses as part of its approach. The employee classification is 11–50, while one current position is specifically listed, so the profile does not provide a consistent basis for estimating current team size. Overall, the evidence supports continued development of a neuroscience-focused consulting and assessment offering, but leaves the pace of commercialization, revenue growth, and organizational scale uncertain.